MarketCap
Facebook
X
TelegramAnnual report 2022
added 03-20-2023
Athenex Operating Income 2011-2026 | ATNX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Athenex
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -70 M | -150 M | -120 M | -119 M | -127 M | -110 M | -85.7 M | -50.7 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -50.7 M | -150 M | -104 M |
Quarterly Operating Income Athenex
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -12.9 M | - | -22.5 M | - | -29.5 M | -40.1 M | -19.2 M | -46.2 M | -29.6 M | -32.3 M | -15.6 M | -21.3 M | -33.6 M | -30.4 M | -34.3 M | -25.4 M | -56.2 M | -37.3 M | -7.87 M | -28.4 M | -16.4 M | -30.8 M | -34.5 M | -37.7 M | -24.6 M | -12.9 M | -10.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -7.87 M | -56.2 M | -27.6 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-15.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.06 | -0.93 % | $ 114 M |  Canada |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
China Pharma Holdings
CPHI
|
-4.59 M | $ 0.55 | -3.51 % | $ 9.61 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 4.58 | -5.37 % | $ 64.4 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-55.6 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.48 | -6.2 % | $ 86.3 M | Canada |
 |
Harrow Health
HROW
|
30.5 M | $ 38.6 | -27.96 % | $ 1.42 B | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.92 | -0.78 % | $ 457 M | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
-244 M | $ 11.9 | 1.06 % | $ 845 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 4.13 | -3.73 % | $ 266 M | USA |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.73 | -3.7 % | $ 2.09 B | Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.87 | -4.33 % | $ 378 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.37 | -3.52 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
-1.12 B | $ 11.39 | -7.89 % | $ 1.58 B | USA |
 |
Rockwell Medical
RMTI
|
-6.67 M | $ 0.9 | -0.12 % | $ 21 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.53 | 0.66 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 2.22 | -0.89 % | $ 23.2 M | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.52 | -3.82 % | $ 340 M | USA |
 |
Viatris
VTRS
|
766 M | $ 14.89 | -5.16 % | $ 17.9 B | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.77 | -4.37 % | $ 3.32 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 22.1 | 3.85 % | $ 1.02 B | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 4.67 | -3.51 % | $ 141 M | USA |
 |
SCYNEXIS
SCYX
|
72.7 M | $ 0.75 | 0.33 % | $ 35.9 M | USA |
 |
Solid Biosciences
SLDB
|
-130 M | $ 5.96 | -3.87 % | $ 243 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 2.75 | -3.17 % | $ 3.41 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 7.36 | -3.16 % | $ 4.55 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |